High materiality8/10
Animal Tester Neogen Sticks To Annual Forecast Despite Tariffs
Why it may matterVerify against the original reporting
NEOG's stock rose significantly after positive sales results and guidance affirmation.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
NEOG reported Q1 2026 sales of $209.19 million, slightly above expectations. Gross margin fell to 45.4% due to production relocations and tariffs. First-quarter adjusted EBITDA was $35.5 million, lower than last year's $43.7 million. Food Safety sales declined 4.6%, while Genomics showed mid-single-digit growth. NEOG affirmed 2026 sales guidance of $820-$840 million, slightly above consensus.
- NEOG reported Q1 2026 sales of $209.19 million, slightly above expectations.
- Gross margin fell to 45.4% due to production relocations and tariffs.
- First-quarter adjusted EBITDA was $35.5 million, lower than last year's $43.7 million.
- Food Safety sales declined 4.6%, while Genomics showed mid-single-digit growth.
- NEOG affirmed 2026 sales guidance of $820-$840 million, slightly above consensus.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.